The company’s 5th birthday marks a significant milestone for XenoGesis, which has seen year-on-year growth since its formation in November 2011.
XenoGesis was borne out of the closure of AstraZeneca’s Charnwood site in Loughborough. Spotting an opportunity in the market, and disillusioned by the state of the Pharma industry, Dr Richard Weaver set up XenoGesis at BioCity Nottingham with support from private investors.
Since then, the team has grown from three to twenty three, taking on more lab space at BioCity in Nottingham, and now works with over 100 clients across the globe.
The company is now the UK’s largest independent laboratory-based contract research organisation specialising in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation.
Reflecting on the last five years, Richard said, “The secret to the success of XenoGesis has been our clear vision and 5 year plan. Moreover, we could not have got to where we are today without the team, who collectively have an enviable track record of delivery in drug discovery. “
He continued, “We know that there is a real need for scientific experimental capability in DMPK, and our clients value the true partnership and consultative approach that we take to help them achieve their drug discovery goals.”
BioCity Group CEO and Non-Executive Director of XenoGesis, Glenn Crocker, added, “XenoGesis is a true example of a BioCity success story. As the UK’s leading bioscience incubator, we provide the infrastructure to those who share the goal of turning new ideas into commercial success. It has been a pleasure to witness XenoGesis’ year-on-year growth, and the creation of new opportunities for skilled scientists here in Nottingham has added to the BioCity community. We wish the team at XenoGesis continued success for many years to come.”
In June of this year, XenoGesis was awarded the prestigious Medilink East Midlands Outstanding Contribution Award in recognition for its achievements.
This autumn also sees the opening of the new Bioanalysis and Metabolic Identification Suite at XenoGesis, which is the result of significant investment in cutting-edge technology.
